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Abstract
Purpose: To evaluate the daily treatment setup variation and the interfraction and intrafraction prostate motion with portal
imaging and implanted fiducial markers during irradiation with a 3D conformal radiotherapy for localized prostate cancer pa-
tients. Methods: By remote verification, shifts from isocenteric positioning and inter/intra-fraction prostate motion were inves-
tigated for 34 patients treated supine with escalated dose conformal radiotherapy. To limit the effect of inter-fraction prostate
motion, patients were planned and treated with an empty rectum and a comfortably full bladder. Daily pre-therapy and treat-
ment electronic portal images were obtained for anterior and lateral treatment fields according to an on-line target localization
protocol using three gold markers. From these images, random and systematic set-up errors were measured by matching corre-
sponding patients’ gold markers on reference digitally reconstructed radiographs (DRR). Superior-inferior, anterior-posterior
and lateral motions were measured from the displacement of the gold markers implanted into the prostate before planning. A
planning target volume (PTV) was derived to account for the measured prostate motion and field placement deviations. Results:
Analysis of 1,278 portal images to determine changes in the radiation field during the course of treatment. From the data, ran-
dom isocenter positioning deviations were 2.66 mm, 2.78 mm and 2.59 mm for vertical, lateral and longitudinal movements
respectively. The systematic deviations were 3.15 mm, 3.09 mm and 2.52 mm for vertical, lateral and longitudinal movements
respectively. From the verification process, it was realized that 44.7%, 42.8% and 31.4% of the vertical, lateral and longitudinal
prostate migrations respectively needed correction/shift. Conclusion: Random set-up errors were small using real-time isocenter
placement corrections. Inter-fraction prostate motion remained the largest source of treatment error, and observed motion was
greatest at the laterals. In the absence of real-time pre-treatment imaging of the prostate position, using sequential portal films
of implanted gold markers, portions of the PTV is missed and surrounding tissues not spared. This research improves quality
assurance by confirming the prostate position within the treatment field over the course of therapy.
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Introduction
The encouraging results of external beam dose escalation
trials for localized prostate cancer patients 1,2,3,4 have
prompted a re-examination of radiation treatment techniques
to establish the best method of safely escalating the dose,
without unduly compromising the treatment volume. Radia-
tion treatments always starts with the acquisition of planning
images 5 and its efficacy depends on the accuracy of patient
setup at each daily fraction. The problem is to reproduce the
patient position and prostate location at the time of acquiring
the planning scans for each fraction of the treatment process.
The PTV includes the Clinical Target Volume (CTV) and
associated treatment uncertainties which includes but not
limited to imaging, patient setup, and organ motion.6 To
analyse the daily movements of the prostate, gold markers are
implanted in the prostate and portal images taken and man-
ually matched with reference images to locate the prostate.
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Geometrical and fiducial markers are annotated onto a highly
quality generated DRRs, that are compared with electronic
portal images (EPIs) acquired right before treatment dose
delivery. Portal images are acquired using an electronic portal
imaging device (EPID).5
The largest motion was observed to be in the anteri-
or/posterior (AP) direction and to a lesser extent in the supe-
rior/inferior (SI) direction. The AP movement was strongly
correlated with rectal filling and then to a lesser extent with
bladder filling.7, 8 The management of target localization
emanates in the concept of treatment margins, described in
the ICRU reports 50 and 62.9, 10 The aim of imaging for
treatment verification is to evaluate the geometric uncer-
tainties both due to organ motion and setup variations
through image guided radiotherapy (IGRT).11 Portal imaging
using bony structures can only detect set-up variations, if
implanted markers are used; both set-up variations and in-
ternal organ motion can be detected and if necessary, cor-
rected.12 Two types of deviations have to be distinguished: the
day-to-day (random) variations and the systematic variations,
present during all treatment fractions.13 Image-guidance
strategies used to reduce setup error are generally classified as
either online or offline procedures. An online approach ac-
quires and assesses information from daily imaging, typically
before every treatment fraction. Simple corrections are im-
plemented to compensate for noted deviations in patient’s
position that exceed a predefined threshold before radiation
delivery. An offline strategy refers to frequent acquisition of
images without immediate intervention.14 In general, online
correction strategies achieve a larger reduction in geometric
errors than offline approaches, but at the expense of more
effort and time at treatment delivery and a higher imaging
dose.
In prostate radiotherapy 7, 15, 16, 17, 18, 19, 20, the actual position of
the prostate can be visualized and verified by using gold
markers as surrogates. The use of implanted markers and
electronic portal imaging has become the gold standard for
daily verification of position and correction of patient setup
and organ displacement errors 21, 22, 23 and is the focus of this
article.
Methods and Materials
In this study, gold markers were implanted into prostate
cancer patients (N = 34) who received external radiation
therapy with 3D conformal radiotherapy for treatment. To
verify the treatment position of the prostate, portal images
(N = 1,278) representing the displacements were acquired
with an iViewGTTM electronic portal imaging device.24 To
analyse patient and prostate position variations, the marker
contours derived from the DRR, were displayed overlaying
the portal image and manually matched. The random error
in the prostate position, derived from the gold markers, is
defined as the Standard deviation (SD) of the day-to-day
variations, averaged over all patients in the group. The sys-
tematic error is defined as the SD of the distribution of aver-
age prostate deviations per patient. For inter-fraction pros-
tate position corrections for both systematic and random
errors, an on-line correction procedure is applied. After
manual alignment of the marker annotations onto the portal
images, the set-up deviations and required corrections are
displayed on iView matching software. Prostate motions in
ventral-dorsal, cranial-caudal and left-right directions are
corrected and intra-fraction prostate deviations checked
again, before the irradiation dose is administered.
Radiation Dose Planning Technique
Each patient had three fine cylindrical gold markers (1 × 8
mm) inserted trans-rectally into the prostate (to serve as a
surrogate for the prostate) under ultrasound guidance by an
urologist before treatment planning. Patients were scanned
supine, with their hips immobilized from the waist to
mid-thigh in a rigid foam cradle and with the lower legs
supported in a soft foam immobilization device. Planning CT
images were taken at 3 mm slice thickness from the top of the
first lumbar vertebrae to below the pelvis. Patients were
asked to empty their bowels (taking 10mg of dulcolax) 2 days
prior to scanning, and their bladder was kept comfortably full
by drinking two glasses of water mixed with 18mls of gas-
trografin 30 min prior to the scan. Planning Magnetic reso-
nance imaging (MRI) scans are also taken and fused with that
of the CT scans. The prescribed dose to the isocentre was 78
Gy in 39 fractions over 7.8 weeks.
Radiation Treatment Technique
The first 4 and 2 monitor units (MUs) of the lateral and ante-
rior treatment fields respectively were used to take portal
images before each fraction; the gold markers from the DRRs
were manually matched unto the images. A shift threshold of
3 mm was used for the prostate migration corrections and any
translations of more than that were corrected before each
treatment. The setup error is estimated and the patient posi-
tion is corrected to reduce the discrepancies between the
localization and reference images. The anterior treatment
fields are used to locate the lateral and longitudinal prostate
motion whiles the lateral treatment fields, are used for the
vertical prostate motion. After the corrections are done
through repositioning of the patients, a verification image is
taken to confirm the shift before the actual treatment is giv-
en.
The iView GTTM Electronic Portal Imaging Device
A standard configuration of the iViewGTTM portal imaging
device includes an amorphous silicon (a-Si) flat mega voltage
(MV) panel image detection system with powerful image
processing and display, using industry standard IT hardware
and software. Under computer control, the fully automated
image acquisition and comprehensive analysis functions are
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presented via a graphical user interface with a single monitor
at the linear accelerator control area. It provides fast radio-
therapy treatment verification for improved patient
throughput. The image is taken when X-rays passing through
the patient activate a fluorescent screen and the amorphous
silicon panel captures the resultant light. The dose required is
low; typically 2 to 4 MUs. iViewGT uses its own
dose-monitoring system to ensure that the optimum dose
from the fluorescent screen and amorphous silicon panel is
used to acquire the portal image. Any displayed image may be
zoomed up to maximum full screen width for closer exami-
nation. Images can also be displayed in the most appropriate
form; window and level gray scale controls, edge enhance-
ment for anatomical sites with less density differential, and
lung and bone inversion for soft tissue identification. Images
can be enlarged, scaled, measured and flipped for better
comparison. The imager had sufficient resolution to reliably
identify the fiducial markers.
Analysis of portal imaging data
Each patient contributed between a range of 34-37 portal
images, and the quality of the images ware excellent and
fiducial markers were clearly identified (Figure 1). The im-
ages were compared to the corresponding DRRs after appro-
priate demagnification, window settings and grey level scale
were applied. Systematic errors in prostate displacement were
calculated as the average of the means of the measured pros-
tate displacements for each patient. After aligning of the
marker positions onto the reference images as shown in Fig-
ure 1, the set-up deviations corrections are displayed and an
on-line correction procedure applied. Lateral (+ sign for left
shift and – sign for right shift), longitudinal (+ sign for supe-
rior and – sign for inferior shift) and vertical shifts (+ sign for
anterior shift and – sign for posterior shift) are done manually
to correct these random and systematic errors before the
actual treatment doses are administered. Random errors were
calculated as the average tendency for errors to occur about
each mean displacement error. No markers were lost or
marker migrations after verification of more than 3.0 mm
(measured in two planes) were observed for any patient.
FIG. 1: Gold markers (green) and field edge (red) annotations on the
DRR and EPI.
Results
The lateral and anterior treatment fields are used to calculate
prostate shifts for all prostate cancer patients undergoing
treatment at the Sweden Ghana Medical Centre (SGMC),
using the iViewGT portal imaging device. From the analysis,
the random error, defined as the standard deviation of the
day-to-day variations, averaged over all patients in the group
and the systematic error defined as the standard deviation of
the distribution of average prostate deviations per patient
were calculated. The results are presented in Table 1 togeth-
er with their maximum deviations. To analyze the data, all
negative signs were ignored to give the true or actual mag-
nitude of deviation regardless of the direction of the gold
markers. Our treatment technique did not permit measure-
ment of rotational set-up errors. The mean representing the
systematic deviations were observed to be associated with
errors transferred from the Treatment Planning System
(TPS) to the Linear accelerator (Linac) or errors in the iView
system itself. The standard deviation, representing the ran-
dom deviations denotes the gold marker (prostate) move-
ments and errors in patient setup. The SD values are very
close to the mean values, meaning that the gold markers
were concentrated around the mean value.
TABLE 1: Components of isocentric positioning error in 34 prostate
cancer patients.
Error type (mm) MAX Systematic Random
VERT 16.0 3.15 2.66
LAT 19.5 3.09 2.78
LONG 15.5 2.52 2.59
FIG. 2: Statistical analysis of gold marker movements in the prostate
during daily setup.
The results (in mm) are prostate position relative to isocenter
systematic deviation and the shifts are isocenter shifts not
couch shifts.
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FIG. 3: Histograms showing the frequency distribution of prostate motion in the various planes.
Implanted fiducial markers allow detection and correction of
organ and/or tumour specific position variations. This image
guided radiotherapy procedure with gold markers and the
EPID has resulted in accurate high-dose, high-precision
prostate treatments, with less toxicity to the bladder and
rectum. Depending on accuracy requirements, off-line cor-
rection protocols appear to be effective in reducing system-
atic deviations at an acceptable workload. With on-line cor-
rections a very high geometric accuracy (<3mm) can be ob-
tained, but at the cost of a considerably larger effort. These
results provided quantitative inter and intra-fractional anal-
ysis of the prostate motion and its individual gold markers.
Discussion
At SGMC, so far, three fine gold markers are implanted in
prostate cancer patients who received external radiation
therapy with 3D conformal radiotherapy planning technique
for treatment. To verify the treatment position of the pros-
tate using an iViewGT verification system, portal images are
acquired with an electronic portal imaging device, using the
first 6 monitor units (MUs) of the treatment beams.
FIG. 4: Two planning images demonstrating an example of prostate
movement during the treatment process with respect to the reference
prostate position.
The gold marker errors identified in this study compare very
favorably to our earlier experience with a bony anatomy
matching technique for prostate cancer radiotherapy. Sys-
tematic errors have been reduced from an average of 4.34 to
2.92 mm and random errors from 3.95 to 2.68 mm. This is
likely attributable to the use of gold markers and the online
corrections used to treat current prostate cancer patients. The
results confirm that prostate motion is the major source of
error in radiation treatment delivery for prostate cancer.
Average prostate motion ranged from 4.54 mm posteriorly to
5.30 mm anteriorly, and 5.72 mm inferiorly to 4.93 mm su-
periorly. These ranges are similar to those observed by these
authors.11, 16, 18, 24 However, despite the large extremes of mo-
tion encountered in some of our patients, the SD for prostate
motion overall was still very narrow, and over 60% of ob-
served movements were actually 3 mm or less. This implies
39.6% of observed patient positioning setup needs shifts or
corrections prior to treatments. Verification images taken for
all treatments fields after the setup correction was done were
below 3mm. Without the use of this daily gold marker
matching, means the patients would have been irradiated
outside the target.
The results of current studies designed to limit set-up errors
and extents of prostate motion are encouraging and demon-
strate true advantages over matching on bony structures
annotation techniques. Overall, the observed prostate motion
tend towards the anterior direction, likely because an empty
rectum protocol which ensures that the prostate was planned
while lying in a posterior position. Prostate motion was
greatest also at the base (inferior), and the least at the apex
(superior). Set-up deviations in lateral, longitudinal and ver-
tical directions are corrected and checked again, before the
irradiation. These represent the intrafraction prostate motion
during the course of the treatments. These shifts or correc-
tions were less than the action level set in all possible direc-
tions for all our 34 patients used for this study.
This method assumes a high degree of correlation between
the prostate target and reference target location in real time.
This reduction in errors due to target motion location permits
the use of high precise doses to the target, which in turn
reduce dose to normal tissues. Ideally, the errors from patient
setup and target motion should be simultaneously corrected
for before treatment, with real-time portal image screening of
implanted gold markers. The newest generation of amor-
phous silicon flat plate imaging device proved to be adequate
for this purpose. The portal images provided excellent reso-
lution of the gold markers, while real time corrections were
done to identify the patients with extreme prostate motion,
and permit corrective action to be taken daily during the
course of treatment.
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Conclusion
A 3DCRT treatment technique for localized prostate cancer
that uses fiducial markers, on-line isocentre verification, and
patient instruction concerning bladder and rectal protocol
resulted in small random and systematic set-up errors as well
as inter/intra-fraction prostatic motion. The results confirmed
that our dose escalation technique for treating prostate cancer
patients are safe since the actual position of the target can be
located on a daily basis.Higher radiation dose levels have been
shown to be associated with improved tumor-control out-
comes in localized prostate cancer patients. They are also
consistently associated with improved biochemical control
outcomes and reduction in distant metastases. Such reduc-
tions reduce the risk of radiation injury to the bladder base
and the bulb of the penis, or permit additional dose to be
given safely to the prostate. Our highly conformal technigue
gives less risk of rectal, bladder and femoral heads toxicity
because of the greater precision in treatment set-up and dose
delivery.
The prostate, known to move independently of bony land-
marks, requires additional effort to visualize its position prior
to radiation delivery. Patient instruction intended to limit
rectal and bladder volumes before treatment may have re-
duced the frequency of large prostate movements, but did not
eliminate them. The use of gold markers and electronic portal
imaging is the gold standard for daily verification of position
and correction of patient setup and organ displacement er-
rors. This report summarizes our experience with this tech-
nique and also compares our formal way of treating prostate
cancer without markers but relaying on bony anatomy for
matching. It was noted that, systematic errors reduced from
an average of 4.34 to 2.92 mm and random errors from 3.95 to
2.68 mm with our current treatment technique. The toler-
ance for the bony anatomy technique was set to 5 mm to
compensate for the movement of the prostate without the
gold markers. Approximately 39.6% of observed patient po-
sitioning setup (using gold markers) needs corrections prior to
treatments as compared 56.8% when matched on bony
anatomy.
In conclusion, the need to use interventions (e.g. IGRT) de-
pends on patient specific motion and treatment geometries.
Surrogate position/movement information (e.g. implanted
markers) play a key role in this area, both validating obser-
vations from 3D patient models, as well as potentially
providing data of acceptable state for treatment.
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